Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.
Brief Summary: The purpose of this study is to examine how well two medicines in combination (solifenacin succinate and mirabegron) work in the treatment of bladder problems over a 12-week period.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: VESIcare® | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: VESIcare®; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: Gabapentin; Type: EXPERIMENTAL; Interventions: Drug: Gabapentin | Arm Label: Solifenacin Succinate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin Succinate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo drugs | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Gabapentin | Intervention Type: DRUG; Name: Solifenacin Succinate; Assigned to Arm(s): Solifenacin Succinate | Intervention Type: DRUG; Name: Placebo drugs; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: SPM 907; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Mirabegron 25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron | Arm Label: Mirabegron 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron | Arm Label: Solifenacin 2.5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin succinate | Arm Label: Solifenacin 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin succinate | Arm Label: Solifenacin 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin succinate | Arm Label: Solifenacin 2.5 mg and Mirabegron 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Arm Label: Solifenacin 2.5 mg and Mirabegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Arm Label: Solifenacin 5 mg and Mirabegron 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Arm Label: Solifenacin 5 mg and Mirabegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Arm Label: Solifenacin 10 mg and Mirabegron 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Arm Label: Solifenacin 10 mg and Mirabegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Intervention Type: DRUG; Name: Mirabegron; Assigned to Arm(s): Mirabegron 25 mg, Mirabegron 50 mg, Solifenacin 10 mg and Mirabegron 25 mg, Solifenacin 10 mg and Mirabegron 50 mg, Solifenacin 2.5 mg and Mirabegron 25 mg, Solifenacin 2.5 mg and Mirabegron 50 mg, Solifenacin 5 mg and Mirabegron 25 mg, Solifenacin 5 mg and Mirabegron 50 mg | Intervention Type: DRUG; Name: Solifenacin succinate; Assigned to Arm(s): Solifenacin 10 mg, Solifenacin 10 mg and Mirabegron 25 mg, Solifenacin 10 mg and Mirabegron 50 mg, Solifenacin 2.5 mg, Solifenacin 2.5 mg and Mirabegron 25 mg, Solifenacin 2.5 mg and Mirabegron 50 mg, Solifenacin 5 mg, Solifenacin 5 mg and Mirabegron 25 mg, Solifenacin 5 mg and Mirabegron 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D